CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-500

Chemistry Review(s)
NDA 21-500

Emtriva® (emtricitabine) Capsules

Gilead Sciences, Inc.

George Lunn
Division of Anti-Viral Drug Products
# Table of Contents

Table of Contents.......................................................................................................................... 2

Chemistry Review Data Sheet.......................................................................................................... 5

The Executive Summary................................................................................................................... 9

I. Recommendations....................................................................................................................... 9
   • A. Recommendation and Conclusion on Approvability.............................................................. 9
   • B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approval................................................................. 9

II. Summary of Chemistry Assessments.......................................................................................... 9
   • A. Description of the Drug Product and Drug Substance.......................................................... 9
   • B. Description of How the Drug Product is Intended to be Used............................................ 11
   • C. Basis for Approvability or Not-Approval Recommendation............................................... 11

III. Administrative............................................................................................................................ 11
   • A. Reviewer’s Signature............................................................................................................ 11
   • B. Endorsement Block............................................................................................................. 11
   • C. CC Block............................................................................................................................ 11

Chemistry Assessment ..................................................................................................................... 12

I. DRUG SUBSTANCE...................................................................................................................... 12
   • 1. Description & Characterization: Acceptable......................................................................... 12
      a. Description.......................................................................................................................... 12
      b. Characterization / Proof Of Structure................................................................................. 13
   • 2. Manufacturer: Acceptable.................................................................................................... 13
   • 3. Synthesis / Method Of Manufacture: Acceptable................................................................. 14
      a. Starting Materials - Specs & Tests...................................................................................... 14
      b. Solvents, Reagents, etc....................................................................................................... 18
c. Flow Chart ........................................................................................................... 24
d. Detailed Description............................................................................................ 26

- 4. Process Controls: Acceptable...........................................................................29
   a. Reaction Completion / Other In-Process Tests ............................................... 29
   b. Intermediate Specs & Tests ........................................................................... 29

- 5. Reference Standard: Acceptable......................................................................38
   a. Preparation ........................................................................................................ 38
   b. Batch Analyses.................................................................................................. 38

- 6. Regulatory Specifications / Analytical Methods: Acceptable.........................39
   a. Drug Substance Specifications & Tests ............................................................ 39
   b. Justification for Specifications ........................................................................ 40
   c. Analytical Methods........................................................................................... 42
   d. Purity Profile .................................................................................................... 45
   e. Microbiology .................................................................................................... 48
   f. Batch Analyses.................................................................................................. 48

- 7. Container/Closure System For Drug Substance Storage: Acceptable.............50

   a. Primary Stability Data ................................................................................... 51
   b. Validation Batches Stability Data .................................................................... 56
   c. Stability Protocols .......................................................................................... 58
   d. Stress Studies ................................................................................................... 58

II. DRUG PRODUCT .................................................................................................60

- 1/2. Components/Composition: Acceptable.......................................................60

   a. Active Ingredient(s) ...................................................................................... 61
   b. Excipients ......................................................................................................... 61

- 3. Manufacturer: Acceptable................................................................................62

- 4. Methods Of Manufacturing And Packaging: Acceptable...............................62
   a. Production Operations .................................................................................... 63
   b. In-Process Controls & Tests ........................................................................... 63
   c. Reprocessing Operations ................................................................................ 63

- 5. Regulatory Specifications And Methods For Drug Product: Acceptable.......63
   a. Sampling Procedures....................................................................................... 64
b. Regulatory Specifications And Methods ................................................. 64

- 6. Container/Closure System: Acceptable ........................................... 70
  a. Container/Closure System in Original NDA ..................................... 70
  b. Container/Closure System in Amendment of 4/25/03 ........................ 70
  c. Container Labels ............................................................................. 71

- 7. Microbiology: Acceptable ................................................................. 72

  a. Primary Registration Stability Batches ............................................. 72
  b. Supportive Stability Batches .......................................................... 75
  c. Other Stability Batches ................................................................. 76

III. INVESTIGATIONAL FORMULATIONS: N/A ........................................ 77

IV. ENVIRONMENTAL ASSESSMENT: Acceptable ................................ 78

V. METHODS VALIDATION: Pending .................................................... 78

VI. LABELING ........................................................................................ 78

VII. ESTABLISHMENT INSPECTION .................................................... 80

VIII. DRAFT DEFICIENCY LETTER ......................................................... 82
Chemistry Review Data Sheet

1. NDA 21-500

2. REVIEW #1

3. REVIEW DATE: 5-Jun-2003

4. REVIEWER: George Lunn

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>20-Aug-2002</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>26-Sep-2002</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>15-Oct-2002</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>26-Feb-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>25-Apr-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>28-Apr-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>29-Apr-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>09-May-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>20-May-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>23-May-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>06-Jun-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>20-Jun-2003</td>
</tr>
<tr>
<td>Amendment</td>
<td>25-Jun-2003</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Page 5 of 86
8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Emtriva [originally submitted as Coviracil]
   b) Non-Proprietary Name (USAN): emtricitabine
   c) Code Name/# (ONDC only): FTC; TP-0006; A-319807.0; D19807; 25053
   d) Chem. Type/Submission Priority (ONDC only):
      • Chem. Type: 1
      • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: N/A

10. PHARMACOL. CATEGORY: Antiviral

11. DOSAGE FORM: Capsule

12. STRENGTH/POTENCY: 200 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _X_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)[Note26]:
   _X_SPOTS product – Form Completed

Page 6 of 86
Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

5-Fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
4-amino-5-fluoro-1-(2R-hydroxymethyl)[1,3]oxathiolan-5S-yl]-(1H)-pyrimidin-2-one
(-)-2',3'-Dideoxy-5-fluoro-3-thiacytidine

Registry Number [143491-57-0]

C₈H₁₀FN₃O₃S  Formula Weight: 247.24

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td></td>
<td>Gelatin capsules</td>
<td>1</td>
<td>Adequate</td>
<td>12/30/02</td>
<td>Reviewed by G. Lunn</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td>bottle</td>
<td>3</td>
<td>Adequate</td>
<td>5/28/02</td>
<td>Review by J. Boal, adequate for a solid oral dosage form</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td>bottle</td>
<td>3</td>
<td>Adequate</td>
<td>5/7/99</td>
<td>Review by R.S. Harapanhalli, adequate for a bottle</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td></td>
<td>induction seal</td>
<td>4</td>
<td>Adequate</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1. Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2. Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>25-Jun-2003</td>
<td>B. Merritt, OC, CDER</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 21-500

The Executive Summary

I. Recommendations

   A. Recommendation and Conclusion on Approvability

      This NDA is recommended for approval from the CMC perspective.

   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approval

      None

II. Summary of Chemistry Assessments

   A. Description of the Drug Substance and Drug Product

Drug Substance

Emtricitabine is an NME reverse-transcriptase inhibitor for the treatment of HIV infection. Emtricitabine is a single enantiomer with two chiral centers. It is a white to off-white watersoluble powder. Three polymorphic forms have been identified but only the most stable Form I is produced by the synthesis, and will be used as the drug substance. The structure of FTC is determined by analysis.

As originally proposed by the sponsor the starting materials were [---]. At the request of the FDA the sponsor opted to designate [---] as starting materials. The specifications for these compounds are reasonable. The synthesis is well described. The reactions are well controlled and the isolated intermediates have comprehensive and appropriate specifications. An early problem that resulted in [---] has been overcome.

The drug substance specifications are comprehensive and appropriate and include specifications for assay, water, residual solvents, particle size, impurities, and chiral purity. At the request of
Executive Summary Section

FDA the limits for: ——— were reduced from ——— and the limit for the enantiomer was reduced from ———. Although rather high the limit for the enantiomer is toxicologically qualified and corresponds to current manufacturing capability. The specifications are justified based on toxicological considerations and the characteristics of 12 recent lots of drug substance made at the commercial site. The analytical methods are described in detail and have been validated.

Late in the review process ——— was introduced as an alternate drug substance manufacturing site. Five lots manufactured by ——— are compared to 12 lots manufactured at the original site ——— and are shown to be similar.

Based on 24 months (3 batches) and 21 months (1 batch) of long-term and 6 months (4 batches) of accelerated stability data on batches manufactured on full to quarter scale, a retest date of 24 months is assigned.

Drug Product

The drug product is a capsule containing 200 mg emtricitabine with microcrystalline cellulose, crospovidone, povidone, and magnesium stearate as inactive ingredients. The inactive ingredients are compendial and the capsule shells are covered by a DMF from ———.

The capsules are manufactured using ———. The manufacturing process is described in detail and the in-process controls are appropriate.

The specifications are appropriate and contain tests for identity, assay, degradants, water, weight variation, dissolution, and aerobic microbial count. Justifications are provided for the specifications. The analytical methods are described in detail and validated. However, discussion of the analytical methods is extremely fragmented. Numerous reports are supplied for each method. Tier 2 testing using an enzyme is provided for the dissolution method. However, Tier 2 testing has not yet been required.

The commercial product will contain 30 capsules in a ——— bottle with a child-resistant closure and an induction seal. Late in the review process an alternate container-closure system was described. The alternate system is similar but consists of components from different manufacturers. Either system is acceptable.

The stability data are generally satisfactory. Although some slowing in dissolution was observed for one batch there were no failures. The sponsor feels that the problem has been solved ———.

The sponsor supplies data to show that this product qualifies for a categorical exclusion from the requirement to file an Environmental Assessment.
Executive Summary Section

A complete Methods Validation package is supplied. The methods have been supplied to FDA laboratories but the results are not expected prior to the approval of this NDA.

An Establishment Evaluation Request was submitted and an overall recommendation of Acceptable has been received.

- **B. Description of How the Drug Product is Intended to be Used**

Emtricitabine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. The recommended daily dose is one 200 mg capsule. Emtricitabine is supplied as a package of 30 capsules in ——— bottle.

An expiration dating period of 24 months is approved, based on 24 months of long-term stability data for one large scale, one pilot scale, and 3 small scale lots and 18 months of long-term stability data for one large scale lot. These data also support the storage statement, “Store at 25 °C (77 °F); excursions permitted to 15 °C – 30 °C (59 °F - 86 °F) (see USP Controlled Room Temperature)”.

- **C. Basis for Approvability or Not-Approval Recommendation**

The drug substance manufacturing process is well controlled and described in detail. The specifications are appropriate and justified and the retest date is supported by appropriate data. The composition, manufacturing process, and specifications for the capsules are appropriate and the expiration dating period is supported by adequate data. The container-closure system and labeling are appropriate. After evaluation all manufacturing sites were found to be acceptable. This NDA is therefore recommended for approval from a CMC perspective.

**III. Administrative**

- **A. Reviewer’s Signature**

  George Lunn, Ph.D. {Signed Electronically in DFS}  Date of draft review 6/5/03

- **B. Endorsement Block**

  Stephen P. Miller, Ph.D.

- **C. CC Block**

  Chi-wan Chen, Ph.D.
Redacted 75

pages of trade

secret and/or

confidential

commercial

information
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
George Lunn
6/27/03 04:01:05 PM
CHEMIST

FTC Review (with EES report)

Stephen Paul Miller
6/27/03 04:14:14 PM
CHEMIST